Core Viewpoint - The company announced the initiation of a Phase II clinical trial in China for its proprietary IL-2 mu-Fc injection, SIM0278, in collaboration with Almirall, targeting moderate to severe atopic dermatitis [1] Group 1 - The clinical trial has officially started at Hangzhou First People's Hospital, marking a significant step in the development of SIM0278 [1] - SIM0278 is a regulatory T cell (Treg) preferential IL-2 mutant fusion protein, indicating its specialized mechanism of action [1]